Date:2/25/2009

------- ------- Total liabilities and stockholders' equity $487,406 $225,687 ======== ======== NuVasive, Inc. Unaudited Condensed Consolidated Statements of Cash Flows (in thousands) Years Ended December 31, ------------------------ 2008 2007 2006 ---- ---- ---- Operating activities: Net loss $(27,528) $(11,265) $(47,910) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 23,105 12,952 8,350 In-process research and development 20,876 - - Stock-based compensation 20,947 13,621 13,345 Leasehold abandonment 4,403 - - NeoDisc technology costs - - 8,060 Allowance for doubtful accounts 1,026 189 125 Allowance for excess and obsolete inventory (836) 514 1,768 Other 179 109 388 Changes in operating assets and liabilities: Accounts receivable (25,152) (8,725) (7,423) Inventory (32,451) (18,026) (8,877) Prepaid expenses and other current assets 274 349 (220) Accounts payable and accrued liabilities 5,098 5,719 3,987 Accrued payroll and related expenses
'/>"/>

SOURCE NuVasive, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine news :

1. NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results
2. NuVasive to Present at Canaccord Adams Musculoskeletal Conference
3. NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference
4. NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results
5. NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference
6. NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference
7. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
8. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
9. NuVasive Acquires First Stem Cell Bone Graft Substitute
10. NuVasive Reports First Quarter 2008 Financial Results
11. NuVasive Prices $200 Million Convertible Senior Notes Due 2013